Edition:
United States

Clinigen Group PLC (CLINC.L)

CLINC.L on London Stock Exchange

760.00GBp
24 Mar 2017
Change (% chg)

0.00 (+0.00%)
Prev Close
760.00
Open
759.00
Day's High
767.50
Day's Low
757.50
Volume
595,142
Avg. Vol
357,306
52-wk High
875.30
52-wk Low
492.75

Latest Key Developments (Source: Significant Developments)

Clinigen group says CEO peter george to step down
Wednesday, 28 Sep 2016 02:08am EDT 

Clinigen Group Plc : Says CEO Peter George to step down on Nov. 11 2016 .Shaun Chilton, current deputy CEO, will become CEO on that date.  Full Article

Clinigen Group reports FY reported revenue 339.9 mln stg
Wednesday, 28 Sep 2016 02:07am EDT 

Clinigen Group Plc : Clinigen group plc: transformational year delivers 25% growth in adjusted EPS . FY 2016 reported revenue £339.9m versus £184.4m . Full year dividend increased 18% to 4.0p . Shaun Chilton to become CEO on 11 November 2016, when Peter George steps down .FY adjusted eps 35.0p.  Full Article

Clinigen and Cumberland Pharmaceuticals launch dry mouth drug in U.S
Monday, 26 Sep 2016 08:30am EDT 

Clinigen Group Plc :Clinigen GrouE and Cumberland Pharmaceuticals launch Rthyol® in U.S.  Full Article

Clinigen, Cumberland enter into U.S. commercialisation deal for ethyol
Tuesday, 10 May 2016 07:00am EDT 

Clinigen Group Plc :Co and Cumberland Pharmaceuticals enter into exclusive u.s. Commercialisation agreement for oncology support drug ethyol.  Full Article

Clinigen Group PLC declares dividend
Wednesday, 23 Sep 2015 06:00am EDT 

Clinigen Group PLC:Proposes a final dividend of 2.3 pence per share.Says this will be payable on Nov. 6 to all shareholders on the register at Oct. 16.  Full Article

Clinigen Group plc proposes dividend
Tuesday, 22 Sep 2015 02:01am EDT 

Clinigen Group plc:Proposes a final dividend of 2.3 pence per share, which when added to the interim dividend of 1.1 pence paid on April 2, will make a total dividend of 3.4 pence per share.Says the final dividend shall be payable on Nov. 6 to all shareholders on the register at Oct. 16.  Full Article

Clinigen to acquire Link Healthcare
Tuesday, 22 Sep 2015 02:00am EDT 

Clinigen Group plc:To acquire Link Healthcare for an initial consideration of £44.5 million and a maximum of approximately £100 million based on achievement of milestones.  Full Article

Clinigen Group PLC New MA program with Neuraltus Pharmaceuticals
Monday, 21 Sep 2015 02:01am EDT 

Clinigen Group PLC:Clinigen Group plc's Idis Managed Access (MA) division and Neuraltus Pharmaceuticals, Inc., announced that the companies are partnering to initiate a Managed Access program for NP001, Neuraltus' investigational therapy for a myotrophic lateral sclerosis.Says the partnership makes the Managed Access program immediately available in selected European countries and is expected to gradually expand over the next year.  Full Article

Clinigen Group plc announces new alliance with Cumberland Pharmaceuticals Inc
Thursday, 17 Sep 2015 02:00am EDT 

Clinigen Group plc:Agrees to a strategic alliance with Cumberland Pharmaceuticals Inc.Says alliance will combine Clinigen's and Cumberland's respective strengths, expertise and geographical footprints to maximize commercial potential of future products.Says that this collaboration will build on Clinigen's existing North American relationships by providing complementary support from Cumberland in development, marketing, promotion and distribution of future products in the US.  Full Article

Clinigen Group Plc and Pharming Group N.V announces global collaboration
Tuesday, 21 Jul 2015 02:00am EDT 

Clinigen Group Plc and Pharming Group N.V:Says their global collaboration to provide access to Pharming's RUCONEST (conestat alfa) is now live.Says unique access program was initiated by HAEi, International Patient Organization for C1- Inhibitor Deficiencies.RUCONEST is recombinant human C1- inhibitor, approved by European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for treatment of acute attacks of hereditary angioedema (HAE).Says "HAEi GAP" program enables patients in all countries where RUCONEST is not commercially available to gain access to the drug through an ethical and regulatory compliant "Named Patient Program" mechanism.  Full Article

More From Around the Web

BRIEF-Clinigen group says CEO peter george to step down

* Shaun Chilton, current deputy CEO, will become CEO on that date Source text for Eikon: Further company coverage: (Bengaluru Newsroom)